Phaseline

Companies › Hanmi Pharmaceutical Company

Hanmi Pharmaceutical Company: clinical trials, targets and expected readouts

11 active drug programs in 12 registered trials: 6 Phase 2, 4 Phase 1, 2 Phase 3; Oncology, Metabolic and endocrine, Gastroenterology, Genitourinary; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HIP2602
Unclear - code-named investigational drug for erectile dysfunction
–Phase 3Erectile DysfunctionSep 2027
Efpeglenatide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 3Type 2 DiabetesNov 2027
HM15275–Phase 2Obese; Type 2 Diabetes MellitusJan 2027
HM15136
Glucagon analog
GCGRPhase 2Congenital HyperinsulinismMay 2027
HM15912 (sonefpeglutide)
GLP-1 receptor agonist
GLP1RPhase 2Short Bowel SyndromeDec 2027
Belvarafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 2Advanced or Metastatic MelanomaSep 2029
Cobimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Advanced or Metastatic MelanomaSep 2029
HM17321
GLP-1 receptor agonist
–Phase 1ObesityMar 2027
BH3120–Phase 1Advanced or Metastatic Solid TumorsAug 2027
HM97662
EZH1/2 dual inhibitor
EZH1, EZH2Phase 1Advanced or Metastatic Solid TumorsJan 2028
HM16390–Phase 1Advanced or Metastatic Solid TumorsJul 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07205900HM15275Phase 2ObeseMetabolic and endocrineJan 2027
NCT07219589HM17321Phase 1ObesityMetabolic and endocrineMar 2027
NCT04732416HM15136Phase 2Congenital HyperinsulinismMetabolic and endocrineMay 2027
NCT06234397BH3120Phase 1Advanced or Metastatic Solid TumorsOncologyAug 2027
NCT07899073HIP2602Phase 3Erectile DysfunctionGenitourinarySep 2027
NCT07527650HM15275Phase 2Type 2 Diabetes MellitusMetabolic and endocrineOct 2027
NCT07379333EfpeglenatidePhase 3Type 2 DiabetesMetabolic and endocrineNov 2027
NCT04775706HM15912 (sonefpeglutide)Phase 2Short Bowel SyndromeGastroenterologyDec 2027
NCT05598151HM97662Phase 1Advanced or Metastatic Solid TumorsOncologyJan 2028
NCT07449754BelvarafenibPhase 2Advanced or Metastatic MelanomaOncologySep 2029
NCT07449754CobimetinibPhase 2Advanced or Metastatic MelanomaOncologySep 2029
NCT06724016HM16390Phase 1Advanced or Metastatic Solid TumorsOncologyJul 2031

Targets

GLP1R (2) GCGR (1) RAF1 (1) BRAF (1) ARAF (1) MAP2K1 (1) MAP2K2 (1) EZH1 (1) EZH2 (1)

Companies with the same targets

Roche Eli Lilly Novo Nordisk Pfizer Novartis AstraZeneca Hangzhou Sciwind Biosciences Day One Biopharmaceuticals Ipsen Pierre Fabre Medicament

Companies built like this

Hangzhou Zhongmei Huadong Pharmaceutical Day One Biopharmaceuticals Shanghai Fosun Pharmaceutical Industrial Development Crinetics Pharmaceuticals Debiopharm International

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.